Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia 3Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 31Rituximab 28Biopsy 23Specimen Handling 20Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 14Vincristine 11Doxorubicin 11obinutuzumab 10Lenalidomide 10Etoposide 10Bendamustine Hydrochloride 9venetoclax 7pembrolizumab 7glofitamab 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5acalabrutinib 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5copanlisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Inotuzumab Ozogamicin × 90 days × Clear all
NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 11 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡